{"contentid": 488207, "importid": NaN, "name": "Pyxis Oncology ends busy month $152 million richer", "introduction": "Just two weeks after announcing a worldwide licensing agreement with Pfizer to develop and commercialize multiple antibody drug conjugates, Pyxis Oncology has announced a $152 million Series B financing.", "content": "<p>Just two weeks after announcing a worldwide licensing agreement with Pfizer (NYSE: PFE) to develop and commercialize multiple antibody drug conjugates (ADCs), Pyxis Oncology has announced a $152 million Series B financing.</p>\n<p>The funding round was led by Arix Bioscience and co-led by RTW Investments, with participation from additional new investors, and brings Pyxis&rsquo; total funding to $174 million.</p>\n<p><span class=\"pullQuote\">\"Immuno-oncology and ADCs represent two of the most promising strategies for treating cancer and we look forward to supporting this team of industry veterans\"</span>Pyxis will use the proceeds from the financing to advance its differentiated portfolio of ADCs, a growing class of therapies that deliver highly potent targeted treatments directly to cancer cells, including PYX-201 and PYX-203, both in-licensed from Pfizer, and PYX-202, recently in-licensed from LegoChem Biosciences (KOSDAQ: 141080).</p>\n<p>The company will also continue advancing its immuno-oncology pipeline to pursue a broad range of therapeutic indications.</p>\n<p>Lara Sullivan, chief executive of Pyxis, said: &ldquo;We are grateful for the support of these highly sophisticated investors as we strive to improve the lives of patients with difficult-to-treat cancers by progressing a diverse portfolio of potentially ground-breaking ADCs and immunotherapies.</p>\n<p>&ldquo;This financing strengthens our ability to build a differentiated portfolio of biologics and allows us to accelerate our efforts to advance multiple promising programs into Phase I clinical trials.&rdquo;</p>\n<p>Christian Schetter, managing director at Arix and board director at Pyxis, added: &ldquo;Our investment reflects our enthusiasm for the strength of both the management team and the company&rsquo;s diverse pipeline of biologics, which have the potential to make a meaningful difference for patients.</p>\n<p>&ldquo;Immuno-oncology and ADCs represent two of the most promising strategies for treating cancer and we look forward to supporting this team of industry veterans as they build on their history of advancing ground-breaking therapies for patients suffering from difficult-to-treat cancers.&rdquo;</p>", "date": "2021-03-30 17:22:00", "meta_title": NaN, "meta_keywords": "Pyxis, ADCs, million, Oncology, financing, Pfizer, multiple, cancer, immuno-oncology, richer, ends, busy, month, worldwide, licensing, promising, antibody", "meta_description": "Just two weeks after announcing a worldwide licensing agreement with Pfizer to develop and commercialize multiple antibody drug conjugates (ADCs), Pyxis Oncolog", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-30 17:02:08", "updated": "2021-03-30 18:51:35", "access": NaN, "url": "https://www.thepharmaletter.com/article/pyxis-oncology-ends-busy-month-152-million-richer", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "pyxis_oncology_large.png", "image2id": "pyxis_oncology_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology, Oncology", "topic_tag": "Business Financing, One to Watch Companies, Research", "geography_tag": "USA", "company_tag": "Pyxis Oncology", "drug_tag": "PYX-201, PYX-203", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-30 17:22:00"}